Latest News
Brodalumab May Reduce Symptoms of Depression and Anxiety in GPP
Postmarketing Study to Evaluate Efficacy and Safety of Spesolimab for GPP Treatment
Mutation Analysis May Be Useful in Women With GPP
New IL36RN Variant Found Unlikely to Contribute to GPP Development
Heterogenous Presentation of GPP Complicates Diagnosis
Interpreting IL36RN Variants for Enhanced GPP Management
Spesolimab May Significantly Reduce the Risk of GPP Flares
AAD and Boehringer Ingelheim Collaborate on AI-Supported Initiative for GPP
Efficacy of Biologics for Generalized Pustular Psoriasis Remains Unclear
Maternal GPP Successfully Treated With Secukinumab
Bimekizumab Remains Under Review by the FDA for Plaque Psoriasis Treatment
Generalized Pustular Psoriasis Exacerbation Linked to G-CSF Use
WES and RNA Sequencing May Be Useful in Assessing GPP and Its Treatment
New Study Suggests Patients With GPP Have Significantly Elevated Mortality Rate
Latest Clinical Trials
Features & Insights
Understanding the Impact of Generalized Pustular Psoriasis on Quality of Life
Dermatological diseases such as generalized pustular psoriasis (GPP) often result in considerable distress among patients due to their outward visibility. Such dermatological diseases burden the patient in two ways: the disease itself, which needs treating, and self-perception and self-esteem issues that can result in considerable psychiatric pathology. There is a dichotomy in medicine when it…
Lack of Diagnostic Consensus for GPP Poses Major Challenges for Physicians and Patients
Despite its distinctive clinical presentation, diagnosis of generalized pustular psoriasis (GPP) poses significant challenges for patients and physicians.
Recognizing and Managing Flares in Generalized Pustular Psoriasis
Due to the rarity of generalized pustular psoriasis, cases often go unrecognized by physicians who are not dermatologists.
Advocates Pushing for Safer, More Accessible Air Travel for People With Disabilities
Rare disease advocacy groups are lobbying Congress to amend regulations to let people with disabilities remain in their wheelchairs during flights.
As Pandemic Restrictions Continue to Ease, Rare Disease Patients Still Fear COVID-19
Three years after COVID-19 was declared a pandemic, rare disease patients still fear the contagion—and must deal with the fallout.
At 40, Orphan Drug Act Enjoys Rare Bipartisan Support
Rare disease advocates are marking the 40th anniversary of the landmark Orphan Drug Act, which has led to over 1100 approvals for new therapies.
Ambitious NCATS Bespoke Gene Therapy Consortium Targets Ultrarare Diseases
The Bespoke Gene Therapy Consortium (BGTC) is an ambitious public-private partnership that aims to develop gene therapies for ultrarare diseases.
EveryLife Foundation Navigates Complex Issues to Advocate for Rare Disease Patients
The EveryLife Foundation for Rare Diseases pushes a legislative agenda aimed at benefitting the 30 million Americans with a rare disease.
The Alliance for Regenerative Medicine Fights for Better Cell, Gene Therapies
The Alliance for Regenerative Medicine aims to help in the development of safe and effective regenerative therapies that can benefit rare disease patients.
‘Fundamental Flaws’ Plague Drug Development Process, Ultragenyx CEO Dr. Emil Kakkis Says
Ultragenyx CEO Dr. Emil D. Kakkis said federal regulators should focus more on biomarkers and less on clinical endpoints when it comes to drug approvals.
An Inspirational Feat: Crossing Spain’s 500-Mile Camino de Santiago by Wheelchair
When 2 friends set out along Spain’s 500-mile Camino de Santiago, they didn’t know how many people they’d inspire with 3 little words: “I’ll Push You.”
- Loading...
Loading...
Loading... 
Loading...